StreetAlpha.app
Home › Stocks › IMDX

Insight Molecular Diagnostics Inc. (IMDX)

$1.97
▲ +18.67%
LAST CLOSE · NOV 20

iMDx develops molecular diagnostic tests for transplanted organ rejection and sells them to hospitals, transplant centers and labs. It last closed at $1.97 on Nov 20, up 18.67% on the day. The next earnings report for IMDX is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, IMDX reported EPS of -$0.10 on revenue of $559,000, with revenue up 115.0% from a year ago. Over its last 8 reports the stock moved an average of 9.4% the session after earnings. Over the last 12 months IMDX insiders bought $11.7M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is IMDX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMDX.

Key Stats

Last 12 months
Results
Revenue
$2.0M
−55.3% vs a year ago
Net income
−$42.1M
−2137.3% margin
EPS (diluted)
−$1.27
Free cash flow
−$32.6M
−1655.5% margin
Valuation
Market cap
$64.5M
32.8M shares
P/E
–
No P/E while losing money
Price to sales
32.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.0M
At Sep 30
Shareholder equity
−$24.2M
Shares outstanding
32.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.2M$2.2MFY2021FY2022: $958K$958KFY2022FY2023: $1.5M$1.5MFY2023FY2024: $1.9M$1.9MFY2024FY2025: $4.1M$4.1MFY2025

From IMDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$0.10
Quarter ended Sep 2026
Year ago EPS
-$0.34
Same quarter last year
Revenue
$559,000
+115.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.30Dec '24Mar 2025: -$0.26Mar '25Jun 2025: -$0.30Jun '25Sep 2025: -$0.34Sep '25Dec 2025: -$0.74Dec '25Mar 2026: -$0.12Mar '26Jun 2026: -$0.31Jun '26Sep 2026: -$0.10Sep '26Latest -$0.10
Revenue by quarter
Dec 2024: $1.5MDec '24Mar 2025: $2.1MMar '25Jun 2025: $518,000Jun '25Sep 2025: $260,000Sep '25Dec 2025: $1.1MDec '25Mar 2026: $32,000Mar '26Jun 2026: $239,000Jun '26Sep 2026: $559,000Sep '26Latest $559,000
How IMDX moved after its last 8 reports
Average move the session after a report ±9.4%
Nov 16, 2026After the close−4.3%
Aug 10, 2026After the close−7.1%
May 13, 2026After the close+25.9%
Mar 26, 2026After the close−13.4%
Nov 10, 2025After the close+10.7%
Aug 11, 2025After the close−3.8%
May 12, 2025After the close−1.4%
Mar 24, 2025After the close−8.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IMDXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on IMDX: 0 upgrades, 0 downgrades, 0 initiations · Targets mentioned $9.00
Lake Street CapitalTarget cut
Nov 21  
StephensReiterated
Nov 21Equal Weight 
BTIGReiterated
Nov 21Neutral 
Lake Street CapitalNew target
Nov 20 $9.00

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on IMDX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IMDX

Technical Analysis

IMDX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 25% below its 20 day and 55% below its 50 day average. It is 124% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $1.87, and the nearest resistance the Pivot R1 at $2.11.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 14.8%/day
Key levels
$7.5152 week high+281.2%
$4.41200 day average+123.9%
$3.81100 day average+93.4%
$3.25Swing high (Oct 27)+65.0%
$3.0550 day average+54.8%
$2.4720 day average+25.4%
$2.11Pivot R1+7.1%
$1.97Last close
$1.87Pivot−5.1%
$1.72Pivot S1−12.7%
$1.5052 week low−23.9%
Indicators
RSI (14)34.61Weak, oversold below 30Neutral
MACD-0.38Below its signal lineBearish
Stochastic14.8Near the bottom of its rangeOversold
ADX (14)36.2Trending down
Williams %R-71.0Oversold below −80, overbought above −20Neutral
CCI (20)-102.0Oversold below −100, overbought above 100Oversold
Rate of change−20.9%Change over 10 sessionsBearish
ATR (14)$0.29Typical daily range, 14.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMDX

What happened before

See how IMDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IMDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IMDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IMDXHow many large options trades hit IMDX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IMDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲26 buying vs 15 selling
  • ●Held by funds +0.2 pts
  • ▲Funds holding +4
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4440+10.0%
In funds' top 1012−50.0%
Held by funds56.6%56.4%+0.3 pts
New / increased13 / 1311 / 10+23.8%
Reduced / sold out7 / 88 / 13−28.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IMDX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$11.7M4 buys · 2 insiders
Sold$00 sales · 0 insiders
2026-02 bought $3.0M2026-04 bought $2.7M2026-11 bought $6.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Broadwood Partners, L.P.10% ownerBuy3,428,571$1.75$6.0M
Apr 27Broadwood Partners, L.P.10% ownerBuy570,184$3.56$2.0M
Apr 20Broadwood Partners, L.P.10% ownerBuy182,861$3.57$653K
Feb 10Neal C Bradsher10% ownerBuy521,739$5.75$3.0M
Feb 7, 2025Patrick W Smith10% ownerBuy1,077,600$2.05$2.2M
Feb 7, 2025Andrea S. JamesCFOBuy97,561$2.05$200K
Every insider buy and sale for IMDX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IMDX insider trades →

From SEC Form 4 filings by IMDX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMDX is in one of them and how their past IMDX trades turned out.

IMDX in the AI portfolios
Loading…

IMDX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMDX in an article yet. Here's the latest on the wider market.

IMDX in the news

About Insight Molecular Diagnostics

iMDx is a diagnostics company based in Nashville, Tennessee. Its main focus is molecular tests that help monitor whether a transplanted organ is being rejected, sold under the GraftAssure name. The test kits are meant for hospitals, transplant centers and labs to run in their own facilities, and research kits are offered to research laboratories. The company also runs a clinical lab in Franklin, Tennessee, and provides assay development and testing services to life sciences and biotechnology companies.

Headquarters
Nashville, TN